Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch–Schönlein purpura nephritis

Immunoglobulin A vasculitis/Henoch–Schönlein purpura (IgAV/HSP) is a major cause of vasculitis in children. It is often accompanied by nephritis (HSPN) and could progress to chronic kidney disease. Galactose‐deficient IgA1 was recently reported to be involved in the pathogenesis of HSPN, for which immunosuppressive drugs are considered key treatment. However, the involvement of immune cells in the development of HSPN remains unclear.

[1]  Yan Cao,et al.  Urinary proteomics of Henoch-Schönlein purpura nephritis in children using liquid chromatography-tandem mass spectrometry , 2020, Clinical Proteomics.

[2]  L. Weber,et al.  Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring , 2018, Pediatric Nephrology.

[3]  Javier Martín,et al.  Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. , 2018, Autoimmunity reviews.

[4]  A. Jamin,et al.  Biomarkers of IgA vasculitis nephritis in children , 2017, PloS one.

[5]  Javier Martín,et al.  A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis , 2017, Scientific Reports.

[6]  H. Inohara,et al.  CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy , 2015, Clinical and Experimental Nephrology.

[7]  R. Coppo,et al.  Henoch–Schönlein purpura nephritis in children , 2014, Nature Reviews Nephrology.

[8]  D. Granville,et al.  Granzyme B Releases Vascular Endothelial Growth Factor from Extracellular Matrix and Induces Vascular Permeability , 2014, Laboratory Investigation.

[9]  R. Sun,et al.  Pentraxin 3 as a novel early biomarker for the prediction of Henoch-Schönlein purpura nephritis in children , 2014, European Journal of Pediatrics.

[10]  F. Schena,et al.  Activated innate immunity and the involvement of CX3CR1-fractalkine in promoting hematuria in patients with IgA nephropathy. , 2012, Kidney international.

[11]  E. Ito,et al.  Imbalance towards Th1 pathway predominance in purpura nephritis with proteinuria , 2011, Pediatric Nephrology.

[12]  E. Riley,et al.  A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG , 2011, European journal of immunology.

[13]  A. Krensky,et al.  Granulysin Delivered by Cytotoxic Cells Damages Endoplasmic Reticulum and Activates Caspase-7 in Target Cells , 2011, The Journal of Immunology.

[14]  H. Yim,et al.  Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria , 2011, Pediatric Nephrology.

[15]  J. Novak,et al.  Pathogenesis of Henoch-Schönlein purpura nephritis , 2010, Pediatric Nephrology.

[16]  Yusuke Suzuki,et al.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. , 2009, The Journal of clinical investigation.

[17]  E. Hasanoǧlu,et al.  HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies , 2007, Clinical Rheumatology.

[18]  A. Anel,et al.  Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis , 2004, The Journal of cell biology.

[19]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[20]  Y. Xia,et al.  Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. , 1999, Kidney international.

[21]  D. Patel,et al.  Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow , 1998, The Journal of experimental medicine.

[22]  A. Howie,et al.  In situ analysis of C-C chemokine mRNA in human glomerulonephritis. , 1998, Kidney international.

[23]  J. Feehally,et al.  Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  N. Yoshikawa,et al.  Multiple combined therapy for severe Henoch-Schönlein nephritis in children , 1998, Pediatric Nephrology.

[25]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[26]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[27]  R. White,et al.  Long-term follow-up of childhood Henoch-Schönlein nephritis , 1992, The Lancet.

[28]  J. Cameron,et al.  Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. , 1987, Kidney international.

[29]  G. Remuzzi,et al.  Kidney diseases , 1913, Immunological reviews.

[30]  T. Sakaguchi,et al.  Effects of Cyclophosphamide Pulse Therapy on the Clinical and Histopathological Findings, Particularly Crescent Formation, in a Patient with Adult-onset Steroid-refractory Henoch-Schönlein Purpura Nephritis. , 2015, Internal medicine.

[31]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.